key: cord-0775538-gr2t993p authors: Yigit, Metin; Ozkaya‐Parlakay, Aslinur; Cosgun, Yasemin; Ince, Yunus E.; Bulut, Yunus E.; Senel, Emrah title: Should a third booster dose be scheduled after two doses of CoronaVac? A single‐center experience date: 2021-09-10 journal: J Med Virol DOI: 10.1002/jmv.27318 sha: 46dc645a5499e56e58f2a4ed4c3d2946ee36cc50 doc_id: 775538 cord_uid: gr2t993p In the 10th month of the pandemic, coronavirus disease 2019 (COVID‐19) vaccination was given first to healthcare workers in Turkey after receiving emergency use approval from the Ministry of Health. This study, which was performed at the COVID‐19 reference center in Ankara (the capital of Turkey) aimed to evaluate the seroconversion rate of the CoronaVac vaccine. The anti‐spike immunoglobulin G response to the two‐dose vaccination was retrospectively examined in healthcare workers who had no previous history of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. The postvaccine seroconversion rate was investigated by measuring the antibody levels of healthcare workers who had received CoronaVac. Vaccination was administered as 600 SU in 28‐day intervals. The healthcare workers' anti‐SARS‐CoV‐2 immunoglobulin G levels were used to determine the seroconversion rate 2 months after the second dose of the vaccine. Of the healthcare workers, 22.9% (n = 155) were seronegative. The younger the age of the participant, the higher the level of anti‐SARS‐CoV‐2 immunoglobulin G. Furthermore, anti‐SARS‐CoV‐2 immunoglobulin G levels were much higher in women than men. Two 0.5-ml doses of the CoronaVac vaccine containing 600 SU of SARS-CoV-2 virus antigen were administered intramuscularly with a 28-day dosing interval. To determine the anti-SARS-CoV-2 immunoglobulin G (IgG) antibody levels, blood samples from 678 HCWs were collected by hospital management 2 months after the second dose of the vaccine. The HCWs, who were volunteers, included pediatricians, pediatric nurses, and auxiliary healthcare staff who worked at the Children's Hospital of Ankara City Hospital. Since individuals who have had prior SARS-CoV-2 infection may generate a higher antibody response to vaccination than those who have not, any participants with a previous history of SARS-CoV-2 infection were excluded from the study. The hospital management organized the sampling, transportation, and timing of the samples before our study. In our study, we analyzed the results of these samples retro- Of the 678 participants, 511 (75.4%) were women, and 167 (24.6%) were men. The mean age was 37.5 ± 9.8 years old, and the median age was 37 years old. The mean age of men was 39.4 ± 9.7 years old, while the mean age of women was 36.8 ± 9.8 years old (Table 1) . When the antibody levels of the HCWs were examined retrospectively, 22.9% (n = 155) of the samples were seronegative (<1), and 77.1% were seropositive. The distribution of the antibody titers was as follows: 22.9% (n = 155) were less than 1; 6.6% (n = 45) were between 1 and 1.99; 20.4% (n = 138) were between 2 and 9.99; 34.2% (n = 232) were between 10 and 99.99; and 15.9% (n = 108) were over 100 (Table 1) . Anti-SARS-CoV-2 IgG levels were much higher in women than in men (p < 0.001; Table 2 ). Additionally, a significant relationship was found between age and anti-SARS-CoV-2 IgG levels (p < 0.001). According to the correlation analyses, the younger the age of the HCW, the higher that individual's levels of anti-SARS-CoV-2 IgG (r = −0.312, p < 0.001; Table 2 ). No relationship was found between age or gender and antibody levels in the seronegative participants (p > 0.05). This study retrospectively evaluated the seroconversion rate of the CoronaVac vaccine using anti-SARS-CoV-2 IgG antibody levels after two-dose vaccination in HCWs with no prior SARS-CoV-2 infection. About one-fifth of the participants were seronegative. To the best of 7 The present study found that vaccine response was better in younger participants than in older participants and that seropositivity rates after two vaccination doses were nearly 78%. The BNT162b2mRNA vaccine produced by Pfizer and BioNTech was the first vaccine approved for emergency use by the United States Food and Drug Administration. 8 The efficiency of BNT162b2mRNA was found to be 95% in a Phase 3 study with more than 43 000 participants, and no significant difference was found between age groups in terms of effectiveness. 9 In the Phase 3 study individuals. Doing so will preserve the continuity of herd immunity until further studies have been conducted. publication. An honorarium, grant, or other forms of payment was not given to any author to produce the manuscript. All authors significantly contributed to the work, have approved the final manuscript, and takes full responsibility for the manuscript. A review of the progress and challenges of developing a vaccine for COVID-19 Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial Development of an inactivated vaccine candidate for SARS-CoV-2 Interım report: safety and immunogenicity of an inactivated vaccine agaınst SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers SINOVAC科兴. 2021. 为人类消除疾病提供疫苗. Accessed US authorization of first COVID vaccine marks new phase in safety monitoring Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine mRNA vaccination induces durable immune memory to SARS-CoV-2 with continued evolution to variants of concern Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants The authors declare that there are no conflict of interests. The data that support the findings of this study are available upon reasonable request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. https://orcid.org/0000-0003-3536-4456Yasemin Cosgun https://orcid.org/0000-0002-3815-8036